Gossamer Bio (NASDAQ:GOSS) Stock Rating Upgraded by Wall Street Zen

Gossamer Bio (NASDAQ:GOSS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

GOSS has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Gossamer Bio in a report on Thursday, September 11th. Scotiabank initiated coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They issued a “sector outperform” rating and a $11.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. Finally, Wedbush boosted their price objective on Gossamer Bio from $4.00 to $5.00 and gave the company an “outperform” rating in a research note on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Gossamer Bio Stock Performance

GOSS stock opened at $2.36 on Friday. The company has a market capitalization of $546.25 million, a P/E ratio of -3.42 and a beta of 1.85. The company has a fifty day moving average price of $2.61 and a 200-day moving average price of $1.88. Gossamer Bio has a 52-week low of $0.66 and a 52-week high of $3.60.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The company had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. As a group, sell-side analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of Gossamer Bio during the second quarter valued at about $26,000. Ciovacco Capital Management LLC bought a new position in Gossamer Bio in the 3rd quarter valued at about $27,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio during the 2nd quarter valued at about $27,000. Drive Wealth Management LLC boosted its stake in Gossamer Bio by 52.7% during the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after purchasing an additional 8,797 shares during the last quarter. Finally, Brighton Jones LLC bought a new stake in Gossamer Bio during the 3rd quarter worth approximately $36,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.